David P. Southwell - 23 Dec 2021 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role: Chief Executive Officer, Director
Signature: /s/ David P. Southwell
Issuer symbol: TCRX
Transactions as of: 23 Dec 2021
Net transactions value: +$95,880
Form type: 4
Filing time: 27 Dec 2021, 15:30:15 UTC
Previous filing: 09 Sep 2021
Next filing: 11 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCRX	Voting Common Stock	Options Exercise	$95,880	+48,670	+50%	$1.97	146,569	23 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCRX	Stock Option (Right to Buy)	Options Exercise	$0	-48,670	-70%	$0.000000	21,161	23 Dec 2021	Voting Common Stock	48,670	$1.97	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares originally subject to this option vested over 4 years of service following October 9, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement).

Content

The shares originally subject to this option vested over 4 years of service following October 9, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement).